Tag: pharmaceuticals
-
Bayer, Boehringer Ingelheim Open Clinical Trial Data
14 May 2014. Two more pharmaceutical companies, Bayer HealthCare and Boehringer Ingelheim, are making detailed data from clinical trials available to the larger scientific community. The two companies join several other pharmaceutical companies taking similar actions over the past several months. Bayer HealthCare in Leverkusen, Germany is making its trial data available through the joint industry…
-
Neurodegenerative Therapies Start-Up Gains $4.8M Seed Funds
12 May 2014. Lysosomal Therapeutics Inc., a start-up developer of therapies for neurodegenerative disorders in Cambridge, Massachusetts, raised $4.8 million in seed financing, the enterprise’s initial operating funds. The company was begun by and is based on the research of Dimitri Krainc, a neurologist at Harvard Medical School and Massachusetts General Hospital in Boston. Atlas…
-
Biopharm, University Partner on Universal Flu Vaccine
8 May 2014. Etubics Corp. in Seattle and University of Texas Medical Branch in Galveston are developing a new type of flu vaccine that aims to provide continuous protection against a variety of seasonal virus strains. The five-year project is funded by a $4.4 million grant from National Institute of Allergy and Infectious Diseases (NIAID),…
-
Immune Therapeutics Start-Up Raises $37.5M in Early Funding
6 May 2014. Anokion SA in Lausanne, Switzerland, a start-up enterprise developing therapies to treat immune systems disorders, raised 33 million Swiss francs ($US 37.5 million) in its first venture financing round. The round was led by Novartis Venture Fund, and two life-science investment companies — Novo Ventures and Versant Ventures — with participation from…
-
Regeneron, Avalanche to Partner on Eye Disorder Gene Therapy
5 May 2014. Regeneron Pharmaceuticals in Tarrytown, New York is licensing gene therapy technology from Avalanche Biotechnologies in Menlo Park, California to develop and commercialize new treatments for eye diseases. The value of the deal is at least $640 million, but not all payment amounts were disclosed. Regeneron is a biopharmaceutical company developing therapies for inflammation, cardiovascular and metabolic disorders, cancer,…
-
Pfizer, Second Genome to Partner on Human Microbes, Obesity
2 May 2014. Second Genome, a biotechnology company in South San Francisco, California, and the pharmaceutical company Pfizer Inc. are conducting a large-scale study to better understand the relationship among gut microbes, obesity, and metabolic disorders, such as diabetes. Financial and intellectual property aspects of the collaboration were not disclosed. Second Genome develops therapies affecting…
-
NYU Medical Center Starts Drug Discovery Partnership Program
1 May 2014. New York University’s Langone Medical Center unveiled an initiative to establish more partnerships with drug and biotechnology companies that move initial therapeutic targets into active drug development programs. NYU’s Office of Therapeutics Alliances, says the university, aims to fill the translation gap or “valley of death” between research performed by academic scientists…
-
MERS Vaccine Candidate Produces Immune Response in Lab Test
30 April 2014. Researchers at the biotechnology company Novavax Inc. in Gaithersburg, Maryland and University of Maryland medical school in Baltimore found new vaccines made from engineered protein nanoparticles generated in lab mice an immune response to the Middle East Respiratory Syndrome (MERS) and severe acute respiratory syndrome (SARS) viruses. The team led by Maryland…
-
Tablet App Provides Feedback, Improves Drug Adherence
29 April 2014. Computer scientists at Carnegie Mellon University in Pittsburgh designed and tested a tablet app, connected to electronic sensors on a pillbox, that provides feedback to older adults and helps them stick to their medication schedules. Anind Dey, a professor in Carnegie Mellon’s Human-Computer Interaction Institute, and former Ph.D. student Matthew Lee, now…
-
Mayo Clinic Offering Gene Test to Target Chemotherapy
29 April 2014. Mayo Clinic in Rochester, Minnesota now offers cancer patients with solid tumors a test that enables physicians to tailor chemotherapy drugs to the patient’s specific genetic background. The test known as Solid Tumor Targeted Cancer Panel or CANCP is available to patients at the Mayo Clinic and its affiliates worldwide, through the…